nach oben

Clinical Drug Investigation

Erschienen in:

01.11.2009 | Original Research Article

Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension

A Retrospective, ‘Real-World’ Comparison with Amlodipine

verfasst von: Dr Masahiro Ohta, Shinichi Sugawara, Noriyuki Sato, Chizuko Kuriyama, Chisho Hoshino, Akio Kikuchi

Erschienen in: Clinical Drug Investigation | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective:Calcium channel antagonists (calcium channel blockers [CCBs]) are often used in the treatment of patients with hypertension to achieve strict blood pressure (BP) targets. In the present study, we compared the antihypertensive effects (determined by home BP [HBP] measurements) and the effects on renal function of benidipine (hydrochloride) and amlodipine (mesylate), a commonly used CCB.

Methods:Changes in HBP and urinary albumin excretion (UAE) were investigated in 47 benidipine and 37 amlodipine recipients with essential hypertension and albuminuria between January 2007 and December 2007.

Results:Both benidipine and amlodipine significantly reduced morning and evening HBP over a 12-month period. Both medications also significantly reduced UAE compared with pretreatment values; however, the reduction in UAE observed in the benidipine group occurred independent of the drug’s antihypertensive effects, whereas a positive correlation was shown between the reduction in morning systolic BP and UAE in the amlodipine group.

Conclusion:These results demonstrate that benidipine favourably affects renal function in patients with essential hypertension compared with amlodipine, suggesting that the clinical benefits of benidipine as an antihypertensive drug include a renoprotective effect.

Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney Int 2005; 68(1): 228–36PubMedCrossRef

Mancia G, DeBacker G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462–536PubMed

The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32(1): 3–107

Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: LIFE study. Ann Intern Med 2003; 139(11): 901–6PubMed

Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31PubMedCrossRef

Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci 2006; 100(4): 243–61PubMedCrossRef

Okumura M, Masada M, Yoshida Y, et al. Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney Int 2006; 70(3): 471–6PubMed

Uzu T, Nishimura M, Fujii T, et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res 2007; 30(3): 161–5PubMedCrossRef

Seino H, Miyaguchi S, Yamazaki T, et al. Clinical effects of a long-acting calcium channel blocker, benidipine hydrochloride, on hypertensive patients with diabetes mellitus: retrospective large scale study of 345 patients [in Japanese]. Endocrinol Diabetol 2006; 22: 371–8

10.

The Japanese Society of Nephrology. The Japanese Society of Nephrology-Chronic Kidney Disease (JSN-CKD) practice guideline 2009. Tokyo: Igakusha, 2009

11.

Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50(3): 560–86PubMedCrossRef

12.

Kamoi K, Miyakoshi M, Soda S, et al. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 2002; 25(12): 2218–23PubMedCrossRef

13.

Kamoi K, Ikarashi T. The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type 2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005; 27(4): 369–76PubMed

14.

Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann Intern Med 1995; 123(10): 754–62PubMed

15.

Akizuki O, Inayoshi A, Kitayama T, et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424–34PubMedCrossRef

16.

Yue W, Kimura S, Fujisawa Y, et al. Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens Res 2001; 24(4): 429–36PubMedCrossRef

17.

Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997; 30(4): 431–6PubMedCrossRef

18.

Hayashi K, Wakino S, Homma K, et al. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005; 99(3): 221–7PubMedCrossRef

19.

Feng MG, Navar LG. Angiotensin II-mediated constriction of afferent and efferent arterioles involves T-type Ca2+ channel activation. Am J Nephrol 2004; 24(6): 641–8PubMedCrossRef

20.

Hansen PB, Jensen BL, Andreasen D, et al. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89(7): 630–8PubMedCrossRef

21.

Yao K, Sato H, Ina Y, et al. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens Res 2003; 26(8): 635–41PubMedCrossRef

22.

Abe M, Okada K, Maruyama T, et al. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3–5 chronic kidney disease. Hypertens Res 2009; 32(4): 270–5PubMedCrossRef

23.

Takenaka T, Takane H, Okada H, et al. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. NDT Plus 2009; 2(2): 192–3CrossRef

24.

Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30(7): 621–6PubMedCrossRef

25.

Ohkubo T, Asayama K, Kikuya M, et al. Ohasama Study: How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 2004; 22: 1099–104PubMedCrossRef

Titel: Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension
A Retrospective, ‘Real-World’ Comparison with Amlodipine
verfasst von: Dr Masahiro Ohta
Shinichi Sugawara
Noriyuki Sato
Chizuko Kuriyama
Chisho Hoshino
Akio Kikuchi
Publikationsdatum: 01.11.2009
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 11/2009
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.2165/11320000-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension

A Retrospective, ‘Real-World’ Comparison with Amlodipine

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

Pancytopenia Associated with Levetiracetam Treatment

Perioperative Use of Nonsteroidal Anti-Inflammatory Drugs

Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer’s Disease

Comparison of the Pharmacokinetics of Apricitabine in the Presence and Absence of Ritonavir-Boosted Tipranavir

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting

Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis